Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Prof. Christoph Wanner
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
From Risk to Results: Cases in ASCVD Prevention and Treatment
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Bridging ASCVD Care Between Academic and Rural Settings
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
When and Why to Use CAC Scoring
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.